We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00564447
First Posted: November 28, 2007
Last Update Posted: September 22, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Merck Sharp & Dohme Corp.
  Purpose
The purpose of this study is to evaluate the drug concentrations of AzaSite™ compared to Vigamox at various time points in conjunctiva tissue of healthy volunteers

Condition Intervention Phase
Bacterial Infections Eye Infections Drug: Azithromycin Drug: Moxifloxacin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Assessment of Pharmacokinetic Parameters [ Time Frame: Up to 24 hours ]
  • Assessment of Pharmacokinetic Parameters [ Time Frame: Over 24 hours ]
    Conjunctiva Concentration of Azithromycin and Moxifloxacin


Enrollment: 48
Study Start Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Azithromycin-30 minutes Post dose Drug: Azithromycin
azithromycin topical solution 1% given as a single drop in a single eye
Other Name: AzaSite
Experimental: Azithromycin-2 hours post dose Drug: Azithromycin
azithromycin topical solution 1% given as a single drop in a single eye
Other Name: AzaSite
Experimental: Azithromycin-12 hours post dose Drug: Azithromycin
azithromycin topical solution 1% given as a single drop in a single eye
Other Name: AzaSite
Experimental: Azithromycin-24 hours post dose Drug: Azithromycin
azithromycin topical solution 1% given as a single drop in a single eye
Other Name: AzaSite
Experimental: Moxifloxacin-30 minutes post dose Drug: Moxifloxacin
Moxifloxacin topical solution given as a single drop in a single eye
Other Name: Vigamox
Experimental: Moxifloxacin-2 hours post dose Drug: Moxifloxacin
Moxifloxacin topical solution given as a single drop in a single eye
Other Name: Vigamox
Experimental: Moxifloxacin-12 hours post dose Drug: Moxifloxacin
Moxifloxacin topical solution given as a single drop in a single eye
Other Name: Vigamox
Experimental: Moxafloxacin-24 hours post dose Drug: Moxifloxacin
Moxifloxacin topical solution given as a single drop in a single eye
Other Name: Vigamox

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Have best corrected visual acuity of 0.60 logMAR or better in each eye as measured using Early Treatment of Diabetic Retinopathy Study chart

Exclusion Criteria:

  • Have a known allergy and/or sensitivity to the test article(s) or its components or any therapies associated with the trial
  • Have active signs or symptoms of any clinically significant ocular disorder (other than refractive disorders)
  • Have a known bleeding disorder or history of bleeding complications after surgical or dental procedures
  • Take aspirin, or take any other blood thinners or anti-coagulants (e.g. warfarin) including prescription, over the counter, or homeopathic therapies
  • Have undergone any ocular surgical intervention within 3 months prior to Visit 1 or anticipate having ocular surgery during the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00564447


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Reza Haque Merck Sharp & Dohme Corp.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Saiid Davari, Inspire Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00564447     History of Changes
Other Study ID Numbers: 041-102
P08654
First Submitted: November 20, 2007
First Posted: November 28, 2007
Results First Submitted: June 27, 2011
Results First Posted: July 26, 2011
Last Update Posted: September 22, 2011
Last Verified: September 2011

Additional relevant MeSH terms:
Infection
Communicable Diseases
Bacterial Infections
Eye Infections
Eye Diseases
Moxifloxacin
Fluoroquinolones
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors